Optimization of current and future therapy for autoimmune diseases.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review.BioMed research international · 2019
   Pooled it
2. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial.Annals of the rheumatic diseases · 2013
   Trial
3. Nanomedicine targeting the PD-1/PD-L1 axis in autoimmune diseases: breaking conventional barriers to restore immune tolerance.Journal of nanobiotechnology · 2025
   Review
4. The role of hypoxic microenvironment in autoimmune diseases.Frontiers in immunology · 2024
   Review
5. Clinical implications of tristetraprolin (TTP) modulation in the treatment of inflammatory diseases.Pharmacology & therapeutics · 2022
   Review
6. Leukocyte metabolism in obese type 2 diabetic individuals associated with COVID-19 severity.Frontiers in microbiology · 2022
   Review
7. Longitudinal patterns of cytokine expression at the individual level in humans after laparoscopic sleeve gastrectomy.Journal of cellular and molecular medicine · 2020
   Article
8. The Next Frontier of Regulatory T Cells: Promising Immunotherapy for Autoimmune Diseases and Organ Transplantations.Frontiers in immunology · 2020
   Review
9. PreAIP: Computational Prediction of Anti-inflammatory Peptides by Integrating Multiple Complementary Features.Frontiers in genetics · 2019
   Article
10. New Therapies of Neovascular AMD-Beyond Anti-VEGFs.Vision (Basel, Switzerland) · 2018
    Review
11. AIPpred: Sequence-Based Prediction of Anti-inflammatory Peptides Using Random Forest.Frontiers in pharmacology · 2018
    Article
12. Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells.Nature medicine · 2017
    Article
13. Neural regulation of immunity: molecular mechanisms and clinical translation.Nature neuroscience · 2017
    Review
14. Mechanisms of Autoantibody-Induced Pathology.Frontiers in immunology · 2017
    Review
15. A Novel Approach to Reinstating Tolerance in Experimental Autoimmune Myasthenia Gravis Using a Targeted Fusion Protein, mCTA1-T146.Frontiers in immunology · 2017
    Article
16. Reprogramming the Local Lymph Node Microenvironment Promotes Tolerance that Is Systemic and Antigen Specific.Cell reports · 2016
    Article
17. Regulatory T cell-based therapies for autoimmunity.Discovery medicine · 2016
    Review
18. Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation.Drugs · 2016
    Review
19. Interferon-beta signaling in retinal mononuclear phagocytes attenuates pathological neovascularization.EMBO molecular medicine · 2016
    Article
20. Regulator of G-protein Signaling (RGS)1 and RGS10 Proteins as Potential Drug Targets for Neuroinflammatory and Neurodegenerative Diseases.The AAPS journal · 2016
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as